Semaglutide prescriptions jump 50% from Dec 2025 to Mar 2026 as oral GLP-1 drugs expand access across retail and telehealth channels.

At the ObesityWeek, Novo Nordisk A/S (NYSE:NVO) presented new findings from the STEP UP phase 3b trial. The Novo Nordisk STEP UP phase 3b trial investigated the efficacy and safety of a higher, 7.2 mg ...

The Medicines and Healthcare products Regulatory Agency has made an announcement affecting people using the weight loss jab ...

Novo Nordisk announced on Tuesday that it is making a higher-dose version of its popular weight-loss medication, Wegovy, available across the United States. The new 7.2-milligram dose, branded as ...

Federal regulators have approved a new, higher-dose version of the obesity drug Wegovy that may help users lose more weight and keep it off. The U.S. Food and Drug Administration approved a ...

Novo Nordisk’s high-dose formulation of its blockbuster weight loss drug Wegovy has been approved by the FDA. The agency approved Wegovy “HD,” a 7.2-mg injection of semaglutide, to reduce excess body ...

Novo Nordisk has released a higher-dose version of its weight-loss drug Wegovy, now available in the U.S. The 7.2-mg dose, named Wegovy HD, was approved recently. While its retail price is $399 ...

April 7 (Reuters) - Novo Nordisk said on Tuesday that it has made a higher-dose version of its blockbuster weight-loss drug ...

Novo Nordisk has launched the first once-daily GLP-1 weight-loss pill, an oral version of Wegovy approved by the FDA last month. Clinical trials showed the Wegovy pill delivered average weight loss of ...

Novo Nordisk has made a higher-dose version of its blockbuster weight-loss drug Wegovy available across the United States.